| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

5-6 December 2018

2018 Citi Global Healthcare Conference

Lotte Hotel

United States

14-15 November 2018

Jefferies London Healthcare Conference

London

United Kingdom

5-7 November 2018

24th Annual International Partnering Conference BIO-Europe-2018

Copenhagen

Denmark

23-24 October 2018

European Alzheimer’s Disease Consortium meeting

Spain

24-27 October 2018

11th Clinical Trials on Alzheimer's Disease, CTAD-2018

Congress Center

Spain

22 October 2018

Oryzon to present at upcoming international conferences

17 October 2018

ORYZON receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)

9 October 2018

Oryzon announces first patient enrolled in REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness

21 September 2018

September 21st: World Alzheimer’s Day around the world

10 September 2018

ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)

Pagination

First page «
Previous page ‹
Page 34
Page 35
Page 36
Page 37
Current page 38
Page 39
Page 40
Page 41
Page 42
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel